← Eichor
Condition: Hereditary Transthyretin Mediated Hattr Amyloidosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hereditary Transthyretin Mediated Hattr Amyloidosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Phase N/A · 40 location(s) · Alnylam Pharmaceuticals · NCT04561518
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos
Phase 3 · 41 location(s) · Alnylam Pharmaceuticals · NCT07223203
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Phase N/A · 82 location(s) · AstraZeneca · NCT06465810
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Phase N/A · 7 location(s) · Alnylam Pharmaceuticals · NCT05040373
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.